6-K ·Filed Jun 15, 2026

CXXIF

C21 Investments Inc.
BULLISH
Impact 7/10
Horizonmonths Processed3mo ago SEC0001062993-26-003202
Notable filing: 6-K
Actionable Insight ▲ Bullish

C21 shareholders should evaluate the implied value of the Vireo stock consideration relative to current CXXIF trading levels. Monitor the shareholder vote and regulatory approval timeline. The deal is expected to close in Q3 2026, after which CXXIF will be delisted.

DirectionBullish
Confidencehigh
Horizonmonths
Latest settled — T+20d
CXXIF ▼ -4.02% at T+20d
LONG call ✗ call lost -4.02% · α vs SPY -3.88% · entry $0.2490 → $0.2390
Next anchor: T+60d due 23d ago
Latest observation: T+22 +20.83% FF3 residual α
Entry anchored
Jun 15, 2026
via day open
T+1d
-3.69%
call -3.69% · α -3.10%
$0.2398
settled 4mo ago
T+5d
-1.20%
call -1.20% · α +1.41%
$0.2460
settled 3mo ago
T+20d
-4.02%
call -4.02% · α -3.88%
$0.2390
settled 3mo ago
T+60d
—
call — · α —
—
due 23d ago

Price Chart

Loading chart...

Executive Summary

C21 Investments Inc. announced a definitive arrangement agreement to be acquired by Vireo Growth Inc. in an all-stock transaction. Each C21 share will be exchanged for 0.023052 Vireo shares, with the deal expected to close in Q3 2026, subject to shareholder and regulatory approvals. This represents a transformative event for C21 shareholders, who will receive equity in a larger multi-state operator.

Key Facts

  • C21 shareholders will receive 0.023052 Vireo shares per C21 share held.
  • Transaction unanimously approved by C21 Board (with interested directors abstaining) and recommended by Special Committee.
  • Needham & Company provided a fairness opinion to C21 Board.
  • Termination fee of US$3,000,000 payable by C21 to Vireo under certain circumstances.
  • C21 shares expected to be delisted from CSE and OTCQX upon closing.
  • Shareholder meeting expected in Q3 2026; deal subject to court and regulatory approvals.
  • Voting support agreements in place with certain C21 directors and officers.

Financial Impact

All-stock acquisition; exchange ratio of 0.023052 Vireo shares per C21 share. No cash consideration disclosed. Termination fee of US$3,000,000.

share priceownership structureliquidity

Risk Factors

  • Shareholder vote may not achieve required two-thirds majority.
  • Regulatory or court approvals could be delayed or denied.
  • Vireo's stock price could decline, reducing the value of consideration for C21 shareholders.
  • Termination fee and deal protection provisions may deter competing bids.

Market Snapshot

Exchange
OTC
Sector
Medicinal Chemicals & Botanical Products

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001062993-26-003202
Document: form6k.htm0001062993-26-003202
Document: 0001062993-26-003202-index-headers.html0001062993-26-003202
Document: 0001062993-26-003202-index.html0001062993-26-003202
Document: 0001062993-26-003202.txt0001062993-26-003202
4 reports for CXXIF
Performance horizon
Filters
Rows
Reports for CXXIF — sortable, filterable
TypeNow
Aug 21, 2026
6w ago
6-K
BEARISH ★ 5/10
$0.2590 awaiting T+20awaiting T+20——
Jun 15, 2026
15w ago
6-K
BULLISH ★ 7/10
$0.2490 $0.2390▼ −4.02%▼ −3.88%—
Jun 12, 2026
16w ago
20-F
MIXED ★ 5/10
$0.2700 $0.2388▼ −11.56%▼ −12.82%—
Jun 12, 2026
16w ago
6-K
MIXED ★ 5/10
$0.2700 $0.2388▼ −11.56%▼ −12.82%—
Showing 4 of 4

US Market Status

Market Closed — Opens Mon (37h 2m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access